Rubedo Life Sciences and Beiersdorf Announce Multi-Year Partnership to Pioneer New Skin Care Products that Address Cellular Aging
Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital
Rubedo Life Sciences is furthering its plan to treat age-related diseases by targeting senescent cells with a $40 million Series A led by Khosla Ventures and Ahren Innovation Capital.
Rubedo Life Sciences Presents In Vivo Efficacy Data Targeting Senescence Cells to Treat Dermatological Diseases
Rubedo Life Sciences Awarded $1.45M in Funding From the California Institute for Regenerative Medicine (CIRM) for Idiopathic Pulmonary Fibrosis Program
Rubedo Life Sciences, a biopharmaceutical company pioneering first-in-class therapies for chronic age-related diseases targeting the senescent cells that drive cellular aging, today announced the appointment of veteran biotech executives Ali Siam as Chief Business Officer and seasoned drughunter Ofir Moreno, Ph.D., as Senior Vice President, Drug Discovery. Both executives will report directly to Rubedo CEO Marco Quarta. Their appointments follow continued momentum at the company, with substantial progress of Rubedo’s small molecule senolytic pipeline and integrated discovery platform.
SUNNYVALE, Calif.--(BUSINESS WIRE)--Rubedo Life Sciences, a biopharmaceutical company pioneering first-in-class therapies for chronic age-related diseases targeting the senescent cells that drive cellular aging, today announced the appointment of veteran biotech executives Ali Siam as Chief Business Officer and seasoned drughunter Ofir Moreno, Ph.D., as Senior Vice President, Drug Discovery. Both executives will report directly to Rubedo CEO Marco Quarta. Their appointments follow continued momentum at the company, with substantial progress of Rubedo’s small molecule senolytic pipeline and integrated discovery platform.
SUNNYVALE, Calif.--(BUSINESS WIRE)--Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies for chronic age-related diseases targeting senescent cells that drive cellular aging, today announced the appointments of Judith Campisi, Ph.D., Francesca Grisoni, Ph.D., and Mario Lacouture, M.D., to its Scientific Advisory Board (SAB). The SAB comprises experts in aging biology, AI, dermatology, drug discovery and development.